AcquisitionFinTech
ARCHIMED acquired Esperion Therapeutics
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
ARCHIMED -> Esperion Therapeutics · $1.1 billion
“ARCHIMED’s acquisition of Esperion provides our shareholders with attractive and immediate upfront value at a compelling premium, while preserving the opportunity to participate in additional upside through contingent milestone payments tied to the future growth of our core cardiometabolic products
Open source record (SEC) ↗